Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage IV Hodgkin lymphoma in Italy

Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage IV Hodgkin lymphoma in Italy

Objectives: Advanced Hodgkin’s lymphoma (HL) is a rare severe neoplasm, significantly limiting the ability of patients to do daily activities among other impacts of the cancer. Many adult patients present with advanced stage disease (stages III/IV). This analysis investigates the cost-effectiveness...

Full description

Bibliographic Details
Main Authors: Chiara Bini, Andrea Marcellusi, Francesco Saverio Mennini, Silvia Ripoli, Laura Fioravanti, Victoria Federico Paly, Alexa Molinari, Paolo Morelli, Stanimira Krotneva, Shujun Li
Format: Article
Language:English
Published: AboutScience Srl 2024-12-01
Series:Global & Regional Health Technology Assessment
Subjects:
Brentuximab Vedotin
Cost-Effectiveness Analysis
Economic evaluation
Hodgkin lymphoma
Online Access:https://journals.aboutscience.eu/index.php/grhta/article/view/3167

Internet

https://journals.aboutscience.eu/index.php/grhta/article/view/3167

Similar Items